KALA — KALA BIO Income Statement
0.000.00%
- $22.07m
- $1.32m
Annual income statement for KALA BIO, fiscal year end - December 31st, USD millions except per share, conversion factor applied.
2020 December 31st | 2021 December 31st | 2022 December 31st | 2023 December 31st | 2024 December 31st | |
---|---|---|---|---|---|
Period Length: | 12 M | 12 M | 12 M | 12 M | 12 M |
Source: | 10-K | 10-K | 10-K | 10-K | 10-K |
Standards: | USG | USG | USG | USG | USG |
Status: | Final | Final | Final | Final | Final |
Revenue | |||||
Total Revenue | 6.36 | 11.2 | 3.89 | 0 | 0 |
Cost of Revenue | |||||
Gross Profit | 3.19 | 7.14 | 1.33 | 0 | — |
Selling / General / Administrative Expenses | |||||
Research And Development | |||||
Unusual Expense / Income | |||||
Other Operating Expenses | |||||
Total Operating Expenses | 103 | 146 | 41.2 | 39.7 | 41 |
Operating Profit | -96.2 | -134 | -37.3 | -39.7 | -41 |
Total Net Non Operating Interest Income / Expense | |||||
Other Net Non Operating Costs | |||||
Net Income Before Taxes | -104 | -143 | -44.8 | -42.2 | -38.5 |
Provision for Income Taxes | |||||
Net Income After Taxes | -104 | -143 | -44.8 | -42.2 | -38.5 |
Net Income Before Extraordinary Items | |||||
Net Income | -104 | -143 | -44.8 | -42.2 | -38.5 |
Income Available to Common Shareholders Excluding Extraordinary Items | |||||
Income Available to Common Shareholders Including Extraordinary Items | |||||
Diluted Net Income | -104 | -143 | -44.8 | -42.2 | -38.5 |
Diluted Weighted Average Shares | |||||
Basic EPS Including Extraordinary Items | |||||
Diluted EPS Including Extraordinary Items | |||||
Diluted EPS Excluding Extraordinary Items | |||||
Normalised Income Before Taxes | |||||
Normalised Income After Taxes | |||||
Normalised Income Available to Common Shareholders | |||||
Diluted Normalised EPS | -99.6 | -106 | -58.7 | -17.4 | -10.1 |